Conatus Pharmaceuticals Acquires Pfizer's Idun Subsidiary - Gilde Healthcare

Conatus Pharmaceuticals Acquires Pfizer’s Idun Subsidiary

July 30, 2010

Former Idun Management team to expand efforts in liver disease and oncology
 
SAN DIEGO – Conatus Pharmaceuticals Inc. announced today that Conatus acquired the Idun Pharmaceuticals subsidiary of Pfizer Inc.  Financial terms were not disclosed.  Conatus Pharmaceuticals is a privately-held drug development company focused on liver disease and oncology.
 
Conatus Pharmaceuticals is led by Steven J. Mento, Ph.D., the former CEO of Idun Pharmaceuticals, which was acquired by Pfizer Inc. in 2005.  

” The addition of Idun to Conatus continues our important work in liver disease and expands our therapeutic reach into oncology,”

said Dr. Mento.

 ” Conatus plans to leverage its scientific and drug development expertise and resources to continue to advance potentially important therapeutic candidates in liver disease and oncology.”

Idun Pharmaceuticals was a privately-held biopharmaceutical company engaged in the discovery and development of drug candidates to control apoptosis. At the time of the acquisition by Pfizer, Idun had a Phase 2 drug candidate in liver disease (emricasan/IDN-6556), preclinical drug candidates including IDN-13389 for oncology, a development agreement with Abbott for an oncology drug candidate, and key intellectual property in the field of apoptosis.  Conatus’ SVP Corporate Development, Jennifer Giottonini Cayer added, ” We appreciate the contributions of Pfizer’s colleagues on these potentially important drug candidates.  Conatus is excited to have the opportunity to work on these programs.”  
 
Conatus Pharmaceuticals Inc. is a privately-held pharmaceutical company engaged in the development of innovative human therapeutics to treat liver disease and oncology. The lead drug candidate, CTS-1027 is in multiple Phase 2 clinical trials for the treatment of hepatitis C virus (HCV).  Conatus was founded by the executive management team of Idun Pharmaceuticals in July 2005 following the sale of Idun to Pfizer. For additional information, please visit www.conatuspharma.com.
 
Source: Conatus Pharmaceuticals

Gilde Healthcare announces successful sale of its outsourced specialist care provider Novicare to Gimv

Gilde Healthcare, the specialized healthcare investor, has reached an agreement on the sale of its Dutch portfolio company Novicare to Gimv*. Novicare provides outsourced medical and paramedical (tele)care services. The company specializes in elderly care...
August 28, 2025

Gilde Healthcare company SynOx Therapeutics Completes Enrollment in Registrational Trial Significantly Ahead of Timeline

DUBLIN, IRELAND, OXFORD, UK, and PHILADELPHIA, PA -- August 5th, 2025 – SynOx Therapeutics Limited (“SynOx”), a late-stage clinical biopharmaceutical company developing emactuzumab for Tenosynovial Giant Cell Tumours (TGCT), today announced completion of patient enrolment...
August 5, 2025

Gilde Healthcare company Shoulder Innovations Announces Pricing of Initial Public Offering

Shoulder Innovations, Inc. (“Shoulder Innovations”), a commercial-stage medical technology company exclusively focused on transforming the shoulder surgical care market, today announced the pricing of its initial public offering of 5,000,000 shares of its common stock...
July 31, 2025